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ABSTRACT
It is currently known that estrogen plays an important role in breast cancer (BC)
development, but the underlying molecular mechanism remains to be elucidated.
Accumulating evidence has revealed important roles of microRNAs in various kinds
of human cancers, including BC. In this study, we found that among the microRNAs
regulated by estrogen, miR-124 was the most prominent downregulated miRNA.
miR-124 was downregulated by estradiol (E2) treatment in estrogen receptor (ER)
positive BC cells, miR-124 overexpression suppressed cell proliferation, migration and
invasion in BC cells; while the suppression of miR-124 using Anti-miR-124 inhibitor
had opposite cellular functions. Under the E2 treatment, miR-124 had stronger
effect to inhibit cellular functions in MCF7 cells than that in MDA-MB-231 cells. In
addition, we identified that ERα, but not ERβ, was required for E2-induced miR-124
downregulation. Furthermore, AKT2, a known oncogene, was a novel direct target of
miR-124. AKT2 expression levels were inversely correlated with miR-124 expression
levels in human breast cancer specimens. AKT2 was overexpressed in BC specimens,
and its expression levels were much higher in ERα positive cancer tissues than those
ERα negative cancer tissues. Consistent with miR-124 suppression, E2 treatment
increased AKT2 expression levels in MCF7 cells via ERα. Finally, overexpression of
miR-124 in MCF7 cells significantly suppressed tumor growth and angiogenesis by
targeting AKT2. Our results provide a mechanistic insight into a functional role of new
ERα/miR-124/AKT2 signaling pathway in BC development. miR-124 and AKT2 may
be used as biomarkers for ERα positive BC and therapeutic effect in the future.

of estrogen receptor β (ERβ), the other subunit of estrogen
receptor, is reduced during tumorigenesis and is important
in terminal differentiation of breast epithelial cells [5, 6].
Estrogen influences numerous cell signal pathways by
activing ERα which is essential for the proliferation of a
large subset of breast tumors [7–9]. Some reports have
shown that estrogen could interfere with repair of mutations
by speeding up the cell division, which may cause the
occurrence of BC [10, 11]. During the development of

INTRODUCTION
Breast cancer (BC) is one of the most common
gynecological malignancies and estrogen receptor α (ERα)
is expressed in about 75% of diagnosed breast tumors
(ERα positive) [1, 2]. Growing evidence manifests that
exposure to estrogens (estrone and estradiol) is an important
determinant of BC risk, and ERα blockers have been widely
used in clinic to treat BC [3, 4]. However, the expression
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molecular mechanisms remain elucidated. miRNAs are
demonstratedto play significant roles in cancer occurrence
and development by inhibiting the expression of their target
genes at post-transcriptional levels. To explore whether
estrogen regulates the expression of certain miRNAs in BC,
the estrogen receptor positive breast cancer cells MCF7
were treated with 10nM E2 or isopyknic solvent ethyl
alcohol (Eth) as control for 24h, then the expression levels
of miRNAs were detected by qRT-PCR. Interestingly,
several miRNAs were significantly upregulated (miR-196a
and miR-200a), or downregulated (miR-7, miR-124
and miR-497) among which miR-124 was the most
significantly downregulated miRNA (Figure 1A). Thus, we
will test the role and mechanism of estrogen-suppressed
miR-124 in BC development in this study. To test whether
E2 inhibits miR-124 expression through the function of
ER, the ER-positive and ER-negative BC cells MCF7 and
MDA-MB-231 were treated with E2 or Eth at different
time points and the results showed that miR-124 expression
was downregulated at 6, 12 and 24 h post E2 treatment in
MCF7 cells (Figure 1B), but not in MDA-MB-231 cells
(Figure 1C), suggesting that ER is necessary for E2 to
inhibit miR-124 expression.

BC, estrogen functions as a tumor promotor by acting
ER which binds to the specific DNA sequences in the
promoter regions of downstream signaling molecules called
estrogen response elements (EREs) [12, 13]. Even almost
all the downstream genes of ER share similar sequences,
however the transcriptional activation effects differ from
each other, which causes multitudinous functions of ER in
BC. Although the carcinogenic role of estrogen in BC has
been extensively explored in the past, the mechanisms of
estrogen in BC are not well understood.
microRNAs (miRNAs) are small (approx. 20-22 nt)
noncoding RNAs which function as post-transcriptional
regulators by negatively regulating the stability or
translational efficiency of their target mRNAs [14, 15].
In recent years, numerous evidences have shown the vital
roles of miRNAs in cancer occurrence and development,
including in BC [16, 17]. For example, miR-21 which
is overexpressed in multiple cancers and functions as
an oncogene by targeting different tumor suppressor
genes, is also upregulated in BC [18–20]. miR-125b is
downregulated in invasive BC and is associated with
poor survival rate by regulating its direct target Ets1 in
BC patients [21, 22]. A few studies indicated miRNAs
may participate in the carcinogenesis process of estrogen
induced BC [23], however, little information is known
about the role and mechanism of miRNAs regulated by
estrogen and their downstream signaling pathways in BC.
In this study, we found that estrogen upregulated
and downregulated the expression of certain miRNAs,
and miR-124 was the most prominent downregulated
miRNAs in response to estrogen treatment. In this study
we aim to address the following questions: (1) whether
estrogen suppresses miR-124 expression through ER, and
which subunit of ER is required for estrogen-regulated
miR-124 downregulation; (2)what is the role of miR-124
in ER positive and ER negative BC cell proliferation,
migration and invasion with ER treatment; (3) what is/
are functional target(s) of the miR-124; (4) whether the
target(s) is/are regulated by estrogen in ER positive breast
cancer cells; and (5) the role of miR-124 in regulating ER
positive breast tumor growth and angiogenesis. The results
of this study will shed light on how estrogen regulates
BC development through regulating miR-124, and will
be helpful for finding new biomarkers and/or therapeutic
targets for ER positive BC.

ERα, but not ERβ, is required for E2-suppressed
miR-124 expression
It is well known that ER is composed by two
subunits ERα and ERβ. To further determine which
subunit of ER is responsible for the downregulation of
miR-124 expression, MCF7 cells were transfected with
siRNAs against ERα, ERβ or negative control (siNC) to
knock down the expression of ERα and ERβ in the cells,
respectively. The results showed that the silence of ERα
significantly inhibited miR-124 expression in a dosedependent manner (Figure 2A). However, there was no
effect of ERβ knockdown on miR-124 expression (Figure
2B), indicating that ERα, but not ERβ, is involved in
regulating miR-124 expression. To further confirm the
role of E2 and ERα in mediating miR-124 expression
upon E2 treatment, we found that E2 decreased miR-124
levels in MCF7 cells, whereas the estrogen antagonist
tamoxifen (TAM) restored miR-124 expression (Figure
2C). E2 or TAM treatment had no effect on miR124 expression in MDA-MB-231 cells (Figure 2D).
Similarly, knockdown of ERα recovered E2-suppressed
miR-124 levels in MCF7 cells, but not in MDA-MB-231
cells (Figure 2E and 2F), demonstrating that miR-124 is
regulated by E2 via ERα.

RESULTS
Estradiol (E2) mediates levels of certain
miRNAs, and miR-124 is the most prominently
downregulated miRNA which is inhibited by
E2 treatment in estrogen receptor (ER) positive
BC cells

Downregulation of endogenous miR-124
levels promotes cell proliferation, migration
and invasion
To identify whether endogenous miR-124 affects
tumor progression, MCF7 and MDA-MB-231 cells were
transfected with miR-124 inhibitor (Anti-miR-124) or

Although the carcinogenic effects of estrogen
in breast tumor are generally accepted, the underlying
www.impactjournals.com/oncotarget
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miR-124 overexpression inhibits E2-induced cell
proliferation, migration and invasion in
ER-positive BC cells

control anti-sense RNA (Anti-miR-NC). Successful
inhibition of endogenous miR-124 expression was
confirmed by qRT-PCR (Supplementary Figure
S1C–S1D). The inhibition of miR-124 remarkably
increased cell growth, migration, and invasion of the
breast cancer cells (Figure 3A-3F), demonstrating the
potential important role of endogenous miR-124 in BC
development. This result also indicates the downregulation
of miR-124 induced by estrogen is involved in estrogenmediated BC progression.

To further study the role of miR-124 in E2promoted BC development, MCF7 and MDA-MB-231
cells were transduced by lentivirus carrying miR-124
or negative control (miR-NC), and the stable cell lines
were obtained by puromycin selection. We found that
E2 treatment significantly increased cell proliferation,

Figure 1: Estradiol (E2) mediates levels of certain miRNAs, and miR-124 is the most prominently downregulated
miRNA which is inhibited by E2 treatment in estrogen receptor (ER) positive BC cells. A. MCF7, the ER-positive BC cells

were cultured estrogen-free medium for 72 h, then treated with 10 nM E2 or equal amount of ethyl alcohol (Eth) as solvent control. The
expression levels of miRNAs were analyzed by qRT-PCR and U6 levels were used as internal control, and normalized to the values of
Eth control. Data were presented as the means ± SD from three independent experiments with triple replicates per experiment. * indicates
significant difference upon E2 treatment at P < 0.05. B. E2 treatment reduced miR-124 expression in MCF7 cells. Cells were cultured with
E2 or Eth for 0, 6, 12 and 24 h. The relative miR-124 expression levels were analyzed as above. Data were presented as the means ± SD
from three independent experiments with triple replicates per experiment. * and ** indicate significant difference under E2 treatment when
compared to solvent control Eth with P < 0.05 and P < 0.01, respectively. C. E2 treatment had no effect on miR-124 expression in MDAMB-231 cells. ER-negative BC cells MDA-MB-231 were treated and miR-124 was detected as above.
www.impactjournals.com/oncotarget
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Figure 2: ERα, but not ERβ, was required for E2-suppressed miR-124 expression. A. Knockdown of ERα in MCF7 cells
induced miR-124 expression. B. ERβ silencing had no effect on miR-124 expression. MCF7 cells were transfected with different dose of
ERα siRNAs, ERβ siRNAs or negative control siRNAs (siNC). After 72 h, the relative expression levels of miR-124 were analyzed by
qRT-PCR and normalized to U6 expression levels. Data were presented as the means ± SD from three independent experiments with triple
replicates per experiment. * and ** indicate significant difference compared to control with P < 0.05 and P < 0.01, respectively. C. E2
treatment decreased miR-124 expression, which was restored by tamoxifen (TAM) treatment. MCF7 cells were cultured in estrogen-free
medium and treated without or with 10 nM E2 and 100 nM TAM for 24 h. The expression of miR-124 was detected as above. Data were
presented as means ± SD from three independent experiments with triple replicates per experiment. ** indicates significant difference
between two groups at P < 0.01. D. E2 and TAM had no effect on miR-124 expression. MDA-MB-231 cells were treated and miR-124 was
analyzed as above. E. Knockdown of ERα recovered E2-suppressed miR-124 levels in MCF7 cells. MCF7 cells were cultured as above,
then transfected with siERα or siNC for 24 h. Cells were treated with or without 10 nM E2 for 24 h and the expression of miR-124 were
detected as above. Data were presented as the means ± SD from three independent experiments with triple replicates per experiment. **
indicates significant difference between two groups at P < 0.01. F. E2 treatment and knockdown of ERα showed no effect on miR-124
expression in MDA-MB-231 cells.
www.impactjournals.com/oncotarget
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Figure 3: Downregulation of endogenous miR-124 promotes the proliferation, migration and invasion of BC cells. A.

and B. MCF7 and MDA-MB-231 cells were transfected with anti-miR-124 inhibitor (Anti-miR-124), or control anti-sense RNA (antimiR-NC). Cell Counting Kit-8 (CCK-8) was used to detect cell vitality every 24 h, and the results were presented as the means± SD from
three independent experiments performed in quintuple. * and ** indicate significant difference compared to anti-miR-NC with P < 0.05
and P < 0.01, respectively. C. and D. The treated cells were used to perform wound healing assay to estimate the ability of cell migration. A
sterile 10 μl pipette tip was used to scratch the cells to form a wound when the different treated cells were cultured to 90% confluence. The
wound gaps were photographed (top) and measured (bottom). Data were presented as the means±SD. ** indicates significant difference
between two groups at P < 0.01 E. and F. The cells above were used to perform Matrigel invasion assay as described. After incubation
for 24 h, the cells in the bottom of the invasion chamber were photographed and the acetic acid-eluted solution was quantified using a
standard microplate reader at 570 nm. Data were presented as the means ± SD from three independent experiments with triple replicates per
experiment. ** indicates significant difference between two groups at P < 0.01.
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whereas forced expression of miR-124 attenuated E2induced cell proliferation in MCF7 cells. In addition, miR124 overexpression also decreased cell growth without
E2 treatment (Figure 4A). Similarly, forced expression
of miR-124 markedly suppressed E2 treatment-promoted
cell migration and invasion in MCF7, the ER-positive BC
cells (Figure 4C and 4E). On the contrary, E2 treatment
had no effect on cell proliferation, migration and invasion
in MDA-MB-231, the ER-negative BC cells. However,
overexpression of miR-124 attenuated cell proliferation,
migration and invasion when compared to miR-NC group
in MDA-MB-231 cells (Figure 4B, 4D and 4F). These
results show that miR-124 acts as a tumor suppressor
toinhibittumor development by attenuating cell viability,
migration and invasion in both ERα-positive and ERαnegative BC cells. More importantly, miR-124 plays an
important role in ERα-positive BC cells to suppress the
estrogen-induced cell viability, migration and invasion,
demonstrating a novel role of miR-124 in E2-regulated BC,
which accounts for about 75% of diagnosed breast tumors.

Next, to determine the expression levels of AKT2 in
clinical BC specimens and adjacent normal tissues, qRTPCR assay was performed to detect AKT2 expression
levels in tissues, then analyzed by densitometric
measurement and normalized to the GAPDH expression
levels. Compared to the adjacent normal tissues, BC
tissues (n = 46) showed significantly higher levels
of AKT2 (P < 0.01, Figure 5E). And for the first time,
we found that ERα-positive BC tissues showed higher
AKT2 expression levels than ERα-negative BC tissues
(P < 0.05, Figure 5F), suggesting that AKT2 may be a
potential biomarker for BC detection and has significance
to differentiate ERα-positive BC in clinical tissue samples.

Forced expression of AKT2 reverses
miR-124-suppressed cell proliferation, migration
and invasion
To determine whether miR-124 inhibits BC
development through its target AKT2, the stable cells of
MCF7 and MDA-MB-231 cells overexpressing miR-124
were transfected with AKT2 cDNA without 3’-UTR. The
immunoblotting results confirmed the effect of AKT2
cDNA transfection (Figure 6A and 6B). Overexpression
of AKT2 was sufficient to reverse miR-124-inhibited
cell proliferation, migration and invasion in both MCF7
(Figure 6C, 6E and 6G) and MDA-MB-231 cells (Figure
6D, 6F and 6H), suggesting that the inhibitory effect of
miR-124 in human BC cells is via the function of its
target AKT2.

miR-124 directly targets and inhibits AKT2
expression, miR-124 levels inversely correlates
with AKT2 expression levels in ERα-positive
BC tissues
To fully understand the mechanisms of miR-124
in suppressing E2 induced BC development, TargetScan
search program was used to predict the targets of miR124. We found AKT2, a well-known oncogene, could be
a potential target of miR-124. The putative binding sites
between miR-124 and 3’-UTR of miR-124 were shown in
Figure 4A. To explore whether miR-124 directly targets
the 3’-UTR of AKT2, we constructed luciferase reporter
plasmids containing the putative wild-type binding
sites (WT) and seed sequence mutant sites (mut) at 3’UTR of AKT2 (Figure 5A) and verified by sequencing.
Overexpression of miR-124 in MDA-MB-231 cells
decreased luciferase activity of wild type reporter to
50%, suggesting that miR-124 may inhibit the 3’-UTR
function of AKT2. To test whether miR-124 specifically
inhibits AKT2 by binding its seed sequence, we also
mutated the miR-124 binding site in the reporter construct
(Mutant). Forced expression of miR-124 did not affect
the transcriptional activation of mutant AKT2 3’-UTR
(Figure 5B). In addition, stable cells of MCF7 and MDAMB-231 overexpressing miR-124 showed decreased
AKT2 expression at protein level (Figure 5C). These
results indicate that AKT2 is a direct target of miR-124 by
binding to the seed sequence. Furthermore, Spearman’s
rank correlation analysis showed an inverse correlation
between expression levels of AKT2 and miR-124 in
human BC specimens (Spearman’s correlation r=-0.3130,
Figure 5D). These results show the negative correlation
between the expression levels of miR-124 and its target
AKT in human BC tissues.
www.impactjournals.com/oncotarget

ERα is required for E2 upregulated-AKT2
expression, which can be inhibited by miR-124
in ERα-positive BC cells
Our previous results demonstrate that E2 regulates
miR-124 expression in ERα-positive cells, but not in
ERα-negative cells. To further study whether E2 affects
expression levels of AKT2, the target of miR-124, we
found that E2 treatment promoted AKT2 expression in
MCF7 cells (Figure 7A), but not in MDA-MB-231 cells
(Figure 7B). E2 treatment induced AKT2 expression to
4.5-fold, whereas TAM treatment decreased E2-induced
AKT2 levels by 50% which was still higher than that in
cells without E2 treatment (Figure 7C). On the contrary,
E2 and TAM showed no effect on AKT2 expression
in MDA-MB-231 cells, which is consistent with our
previous results showing that E2 and TAM did not
regulate miR-124 levels in MDA-MB-231 cells (Figure
7D). Furthermore, without E2 treatment, knockdown
of ERα significantly increased AKT2 expression levels
(P < 0.05) in MCF7 cells. Although the expression
levels of AKT2 are higher in MCF7 cells under the
treatment of E2 combination with ERα knockdown
when compared to the cells ERα knockdown without
E2 treatment, ERα is necessary for E2-induced AKT2
36945
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Figure 4: miR-124 overexpression inhibits E2-induced cell proliferation, migration and invasion in ER-positive BC
cells. The estrogen-positive and -negative cell lines MCF7 and MDA-MB-231 were infected with lentivirus carrying miR-124 or miR-NC

to establish stable cell lines. A. MCF7/miR-124 and MCF7/miR-NC stable cells were plated at 2,000 cells/well in 96-well plates. After
adherence, cells were treated with E2 or Eth solvent. Cell Counting Kit-8 (CCK-8) was used to detect cell vitality every 24 h and the results
were presented as the means± SD from three independent experiments performed in quintuple. * and ** indicate significant difference
compared to miR-NC without E2 treatment group with P < 0.05 and P < 0.01, respectively; # and ## indicate significant difference upon E2
treatment with P < 0.05 and P < 0.01, respectively; & and && indicate significant difference when compared to miR-NC with E2 treatment
group with P < 0.05 and P < 0.01, respectively. B. MDA-MB-231/miR-124 and MDA-MB-231/miR-NC stable cells were treated and
analyzed as above. ** indicates significant difference compared to miR-NC without E2 treatment group at P < 0.01. C. and D. The stable
cells above with or without E2 treatment were used to perform wound healing assay to estimate the ability of cell migration. A sterile 10
μl pipette tip was used to scratch the cells to form a wound when the different treated cells were cultured to 90% confluence. The wound
gaps were photographed (top) and measured (bottom). Data were presented as the means± SD. * and ** indicate significant difference
between two groups with P < 0.05 and P < 0.01, respectively. E. and F. The stable cells above were used to perform Matrigel invasion
assay as described. In addition, the E2 or Eth solvent was mixed into the medium respectively in the lower chamber. After incubation
for 24 h, the cells in the bottom of the invasion chamber were photographed and the acetic acid-eluted solution was quantified using a
standard microplate reader at 570 nm. Data were presented as the means ± SD from three independent experiments with triple replicates per
experiment. * and ** indicate significant difference between two groups with P < 0.05 and P < 0.01, respectively.
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expression. However, neither E2 treatment nor ERα
knockdown showed effect on AKT2 expression in
MDA-MB-231 cells (Figure 7E and 7F). Although
E2 treatment significantly induced AKT2 expression
in MCF7 cells, but not in MDA-MB-231 cells, forced
expression of miR-124 suppressed AKT2 expression
with or without E2 treatment in both cells (Figure 7G–
7J). In addition, silence of miR-124 by siRNAs reversed
the AKT2 suppression caused by the interference of

ERα in ER positive BC cells, and our result indicated
high correlation between ERα and AKT2 levels via
miR-124 levels (Figure 7K–7M).

Overexpression of miR-124 inhibits tumor
growth and angiogenesis
Finally, to further investigate the role of miR-124
in breast tumor growth and angiogenesis in vivo, ectopic

Figure 5: miR-124 directly targets and inhibits AKT2 expression, miR-124 levels inversely correlates with AKT2
expression levels in ERα-positive BC tissues. A. Putative seed-matching sites (in bold) or mutant sites (red) between miR-124

and 3’-UTR of AKT2. B. Luciferase reporter assay was performed using MDA-MB-231 cells to detect the relative luciferase activities of
WT and mut AKT2 reporters. Renilla luciferase vector was used as an internal control. Data were presented as the means± SD from three
independent experiments with triple replicates per experiment. ** indicates significant difference compared to control at P < 0.01. C. The
expression of AKT2 and GAPDH was determined using immunoblotting in MCF7 and MDA-MB-231 cells overexpressing miR-124 and
miR-NC. The densities of AKT2 were quantified by ImageJ software and GAPDH levels were used as internal control, and normalized to
the values of Eth control. Data were presented as the means ± SD from three independent experiments with triple replicates per experiment.
** indicates significant difference compared to control at P < 0.01. D. Spearman’s correlation analysis was used to determine the correlation
between the expression levels of AKT2 and miR-124 in human BC specimens (n=46). Data were presented as the means ± SD from three
independent experiments with triple replicates per experiment. E. The expression levels of AKT2 in adjacent normal tissues and human
BC specimens were determined by qRT-PCR, and the fold changes were obtained from the ratio of AKT2 to GAPDH levels. Data were
presented as mean from three independent experiments with triple replicates per experiment. ** indicates significant difference comparing
normal tissues at P < 0.01. F. The relative AKT2 expression levels of BC tumors were analyzed according to ERα status (ERα-negative,
n=17; ERα–positive, n =29). Data were presented as mean from three independent experiments with triple replicates per experiment. *
indicates significant difference comparing ERα-negative and ERα–positive tumors at P < 0.05.
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Figure 6: Forced expression of AKT2 reverses miR-124-suppressed cell proliferation, migration and invasion. miR-

124- or miR-NC-overexpressing cells were transfected with vector or AKT2 cDNA without 3’-UTR. A. and B. The expression levels
of AKT2 and GAPDH were determined by immunoblotting after 48 h. C. and D. Cell viability was detected using CCK-8 assay. Data
were presented as the means ± SD from three independent experiments with triple replicates per experiment. * and ** indicate significant
difference compared to miR-NC+vector group with P < 0.05 and P < 0.01, respectively. # and ## indicate significant difference compared
to miR-124+vector group with P < 0.05 and P < 0.01, respectively. E. and F. Cells were treated and wound healing assay was performed
as above. Data were presented as the means ± SD from three independent experiments with triple replicates per experiment. ** indicates
significant difference compared to miR-NC+vector group at P < 0.01; ## indicates significant difference compared to miR-124+vector
group at P < 0.01. G. and H. Transwell invasion assay was performed as above using control cells and cells overexpressing miR-124 with
or without AKT2 overexpression. Data were presented as the means ± SD from three independent experiments with triple replicates per
experiment. ** indicates significant difference compared to miR-NC+vector group at P < 0.01; ## indicates significant difference compared
to miR-124+vector group at P < 0.01.
www.impactjournals.com/oncotarget
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Figure 7: ERα is required for E2 upregulated-AKT2 expression, which can be inhibited by miR-124 in ERα-positive
BC cells. A. and B. MCF7 and MDA-MB-231 cells were cultured as above and treated with E2 for 0, 6, 12 and 24 h. The relative AKT2

expression of each group was analyzed by qRT-PCR and represented the ratio to control group. Data were presented as the means ± SD from
three independent experiments with triple replicates per experiment. ** indicates significant difference compared to control at P < 0.01.
C. and D. TAM was used as the E2 antagonist and the expression levels of AKT2 were analyzed by qRT-PCR. Data were presented as the
means ± SD from three independent experiments with triple replicates per experiment. * and ** indicate significant difference between two
groups with P < 0.05 and P < 0.01, respectively. E. and F. Cells were cultured and treated as in Figure 2E, the expression levels of AKT2
were analyzed as above. Data were presented as the means ± SD from three independent experiments with triple replicates per experiment.
** indicates significant difference between two groups at P < 0.01. G. and H. The cells were cultured as above and the expression levels of
AKT2 were determined by qRT-PCR in miR-124- and miR-NC-overexpressing cells without or with E2 treatment for 24 h using GAPDH
levels as internal control, and normalized to the value of Eth control. Data were presented as the means ± SD from three independent
experiments with triple replicates per experiment. * and ** indicate significant differences between two groups with P < 0.05 and P <
0.01, respectively. I. and J. The expression levels of AKT2 and GAPDH were determined by immunoblotting in miR-124- and miR-NCoverexpressing cells without or with E2 treatment for 48 h. The densities of AKT2 were quantified by Image J software and GAPDH levels
were used as internal control, and normalized to the values of Eth control. Data were presented as the means ± SD from three independent
experiments with triple replicates per experiment. * and ** indicate significant differences between two groups with P < 0.05 and P < 0.01,
respectively. K. and L. MCF7 and MDA-MB-231 cells were cultured as above and transfected with siRNAs, and divided in four groups
including siNC+Anti-miR-NC, siERα+Anti-miR-NC, siNC+Anti-miR-124, siERα+ Anti-miR-124 group. After 24 h, the expression levels
of AKT2 were determined by qRT-PCR using GAPDH levels as internal control, and normalized to the values of siNC+Anti-miR-NC
group. Data were presented as the means ± SD from three independent experiments with triple replicates per experiment. ** indicates
significant difference between two groups at P < 0.01 M. and N. Cells were cultured as above and transfected with Anti-miR-NC or AntimiR-124. After 24 h, the cells were treated with or without 10 nM E2 and 100nM TAM for 24 h. The expression levels of AKT2 were
determined by qRT-PCR using GAPDH levels as internal control, and normalized to the values of Eth+Anti-miR-NC group. Data were
presented as the means ± SD from three independent experiments with triple replicates per experiment. ** indicates significant difference
between two groups at P < 0.01.
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Figure 8: Overexpression of miR-124 inhibits tumor growth and angiogenesis. A. MCF7/miR-124 and MCF7/miR-NC cells

were dispersed in 100 μl of serum-free DMEM medium and were subcutaneously injected into both sides of posterior flank of the nude
mice (n=4). Tumors were measured every two days since they were apparently seen and the volumes were calculated using the following
formula: volume = 0.5 × Length × Width2. * and ** indicate significant difference compared to miR-NC group with P < 0.05 and P <
0.01, respectively. B. The tumor was excised and weighed after 17 days. Data were presented as the means ± SD. ** indicates significant
difference compared to miR-NC group at P < 0.01. C. The representative pictures of trimmed tumors (Bar= 10mm). D. The expression
levels of CD31 were analyzed in tumor tissues by immunohistochemistry. The density of CD31 levels was quantified by ImageJ software.
Magnification, ×200, Scale bar, 20 μm. E. The whole protein was extracted from xenografts and subjected to immunoblotting assay for
AKT2 expression. GAPDH expression was served as an internal control.

transplantation model of human BC in nude mice was
employed.MCF7 cells overexpressing miR-124 or miRNC were subcutaneously injected into both posterior
flanks of nude mice. Tumor volumes were monitored
every two days when they were palpable during the
tumor inoculation period.Compared to miR-124 group,
the tumor size of miR-NC group was significantly
increased by Day 11 (P < 0.05) and grew more and more
quickly (Figure 8A). Nude mice were sacrificed 17 days
after implantation and xenografts were trimmed out. The
tumor size of miR-124 group was smaller than that of
control group (Figure 8C). Consistent with tumor size,
the tumor weight of miR-124 group was 31% of control
group (Figure 8B).
Moreover, tumors from MCF7/miR-124 group
showed decreased number of microvessels with CD31
www.impactjournals.com/oncotarget

positive staining by 68% when compared to control
group (Figure 8D). In agreement with the results in vitro,
overexpression of miR-124 suppressed AKT2 expression,
in tumor tissues (Figure 8E). These results suggest that
miR-124 suppresses tumorigenesis and angiogenesis of
human ERα-positive BC in nude mice, and AKT2 is an
important target involved in this process.

DISCUSSION
Estrogen has been reported to play an important
role in tumor occurrence and development during
the past several decades [24]. Estrogen always acts
as a carcinogenic factor by multiple aspects such as
promoting cell proliferation, metastasis and drugresistance of BC cells [3]. The effects of estrogen
36950
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direct target of miR-124, which was confirmed by clinical
BC specimens showing that miR-124 levels inversely
correlate with AKT2 expression levels. AKT2 was shown
to be upregulated in ERα-positive BC tissues. miR-124
may act as a tumor suppressor to inhibit BC development
by targeting AKT2, and ERα is required for E2 upregulatedAKT2 expression, which can bereversedby miR-124 in ERαpositive BC cells. Our results demonstrate a key role of a new
regulatory circuitof E2/ERα/miR-124/AKT2 in mediating
tumor angiogenesis and cancer progression in BC.
In summary, we have demonstrated that miR-124 is
one of the miRNAs which are regulated by estrogen levels.
The downregulation of miR-124 by E2 in ER-positive BC
cells is through ERα but not ERβ, which will broaden our
understanding the mechanisms of estrogen-modulated BC.
Besides, we identified AKT2 as a novel target of miR-124,
which is upregulated in clinical BC specimens, which may
be used to differentiate ERα-positive and –negative BC.
Similar to E2-downregulated miR-124, E2 induces AKT2
expression through ERα. The new regulatory circuit of
E2/ERα/miR-124/AKT2 in BC plays an important role in
BC tumorigenesis and development, which will provide
potential novel biomarkers and targets for the diagnosis
and treatment of BC.

in BC have been widely studied; however, the
underlying molecular mechanisms of estrogen in BC
are still unclear. miRNAs are endogenous small noncoding RNAs, and play critical roles in cell growth,
differentiation, apoptosis and tumourigenesis by
negative regulating the mRNAs of oncogenes or tumorsuppressor genes [25, 26]. Some studies indicatethat
miRNAs may play important roles in estrogen
induced BC [27, 28]. It was showed that miR-5155p was downregulated by estrogen treatment in ER
positive BC cells to regulate the BC cell proliferation
through its target SK1 [1]. ERα upregulated c-Myc
expression which can downregulate ERα as a negative
autoregulatory feedback loop [29]. However, there
is still lack of the knowledge about the roles of
estrogen-regulated miRNAs in BC development. In
this study, we demonstrated that E2 could upregulate
or downregulate certain miRNAs, and miR-124 was
the most prominently downregulated miRNA which
is regulated by E2 treatment in ER-positive BC cells.
miR-124 has been reported to act as a tumor suppresser
in many cancers including BC [30–32]. In this study,
we discovered that estrogen-regulated miR-124 plays
an important role in BC cell proliferation, migration,
invasion, tumor growth and angiogenesis, and also
identified that miR-124 suppression caused by E2
in ER-positive BC cells is through ERα instead of
ERβ. Some reports indicated that ERα instead of ERβ
interacts with and suppresses Drosha activity through
which could downregulate numbers of miRNAs in ERpositive BC cells that were similar to our data [33],
however, the in-depth mechanisms of downregulation of
miR-124 induced by estrogen remains to be elucidated.
Our previous studies have showed that miR-124
could govern glioma growth and angiogenesis and enhance
chemosensitivity by targeting R-Ras and N-Ras [34]. It was
also reported that miR-124 inhibited cellular proliferation
and invasion by targeting Ets-1 in breast cancer cells [35].
Although there were several identified targets of miR-124
which participated in miR-124 mediated BC development
and progression, the researches about the functions and
mechanisms of estrogen downregulated miR-124 in ER
positive BC cells are still scanty. It has been reported that
the activated AKT2 phosphorylates ERα and promotes the
transcriptional activity of ERα [36, 37]. Interestingly, ERα
can also activate AKT2 although the underlined mechanism
is still unknown [36]. There is a correlation between ERα
and AKT2. AKT2 (v-AKT murine thymoma viral oncogene
homologue 2), an isoform of AKT family, is a significant
member of the the PI3K/AKT pathway [38, 39]. Increasing
studies demonstrate the important role of AKT2 in cancers
as an oncogene [40] which is closely associated to tumor
aggressiveness by enhancing the survival, migration and
invasion of cancer cells primarily [36, 41], and overexpress
in many human tumors including BC and ovarian cancer
[42]. In this study, we discovered that AKT2 was a new
www.impactjournals.com/oncotarget

MATERIALS AND METHODS
Human tissue samples
Human BC samples and adjacent normal tissues
were obtained from patients in the First affiliated hospital
of Anhui Medical University, Hefei, China and the Huai’an
First People’s Hospital, Nanjing Medical University.
Tissue samples were collected at surgery, immediately
frozen in liquid nitrogen and stored until total RNAs or
proteins were extracted. All experiments were approved
by the ethics committee of Anhui Medical University and
Nanjing Medical University.

Cell culture
BC cell lines MCF7 and MDA-MB-231 were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS), 100 units of penicillin/mL and 100 ng of
streptomycin/mL. Human embryonic kidney 293T(HEK293T) cells were cultured in DMEM supplemented with
10% FBS, penicillin(100U/ml), streptomycin(100ng/ml)
and 2 mmol/mL glutamine. All cell lines were maintained
in a 37°C incubator with 5% CO2.Before treatment with
estradiol (17β-estradiol, E2; Sigma-Aldrich Ltd.), ethanol
solvent (Eth, used as negative control), or tamoxifen
(Sigma), cells were maintained for 3 days in DMEM
without phenol red (Gibco) supplemented with 10%
double charcoal–stripped FCS (Gibco) and pen/strep
at 37°C with 5% CO2. On the day of treatment, media
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seed regions of AKT2. All the constructs containing
3’UTR inserts were sequenced and verified.
MDA-MB-231 cells (1.0×105/well) were seeded in
24-well plates. After 24 h, cells were co-transfected with
either wild-type (WT) or mutant-type (mut) luciferase
reporter plasmids containing AKT2-3’-UTR, pGL4.74
vector control (Ambion) and equal amounts of premiR-124 or pre-miR-NC using Lipofectamine 2000
(Invitrogen) according the manufacturer’s instruction.
Luciferase activities were measured 24 h after transfection
using the Dual Luciferase Reporter Assay System
(Promega). Experiments were performed in triplicate with
three independent replicates.

was changed to DMEM without phenol red (Gibco)
supplemented with 10% FCS (Gibco) and 100 U/mL
penicillin and 100 ng/mL streptomycin.

Lentiviral packaging and stable cell line
establishment
The lentiviral packaging kit was purchased from
Open Biosystems (Huntsville). Lentivirus carrying
miR-124 or negative control (miR-NC) was packaged in
293T cells and collected from the supernatant as instructed
by the manufacturer’s manual.The lentiviruses were
infected into MCF7 or MDA-MB-231 cells to establish
stable cell lines,followed by puromycin selection.

Protein extraction and immunoblotting

Isolation of RNA, reverse transcription PCR and
quantitative real-time PCR

Cells or tissues grounded in liquid nitrogen were
lysed on ice for 30 min in radioimmunoprecipitation assay
(RIPA) buffer (150 mM NaCl, 100 mM Tris, pH 8.0, 0.1%
sodium dodecyl sulfate (SDS), 1% Triton X-100, 1%
sodium deoxycholate, 5 mM EDTA, and 10 mM NaF)
supplemented with 1 mM sodium vanadate, 2 mM aprotinin,
2 mM leupeptin, 1 mM phenylmethylsulfonyl fluoride,
1 mM dithiothreitol, and 2 mM pepstatin A. The lysates
were centrifugated at 12,000 rpm at 4°C for 15 min, the
supernatants were collected, and protein concentrations were
determined using bicinchoninic acid assay. Protein extracts
were separated by SDS–polyacrylamide gel electrophoresis
and transferred to nitrocellulose membranes in transfer
buffer (20 mM Tris, 150 mM glycine, 20% [volume/volume]
methanol). Membranes were blocked with 5% nonfat dry
milk for 2 h and incubated with primary antibodies (AKT2,
Proteintech; GAPDH, Abcam). The protein bands were
probed with secondary antibody, and visualized with the elec
trochemiluminescencedetection system (Thermo Scientific).

Total RNA was isolated from cultured cells or human
tissues with TRIzol reagent according to the manufacturer’s
instruction (Invitrogen). To determine the quantity of the
mRNA levels of AKT2, total RNAs were reverse transcribed
by oligodeoxythymidine primer using the PrimeScript RT
Reagent Kit. The housekeeping gene GAPDH was used as an
internal control. The primers were as follows: AKT2 forward
primer, 5’- ACCACAGTCATCGAGAGGACC -3′;AK
T2 reverse primer, 5′-GGAGCCACACTTGTAGTCCA-3′;
GAPDH forward primer, 5′-CCACCCATGGCAAATTCC
ATGGCA-3′; GAPDH reverse primer, 5′-TCTAGACGGCA
GGTCAGGTCCACC-3′. To measure the expression levels
of miR-124, the stem-loop specific primer method was
used as described previously [43, 44]. Quantitative reverse
transcriptase (qRT) PCR primers were the following: miR124 RT primer, 5′- CTCAACTGGTGTCGTGGAGTC
GGCAATTCAGTTGAGGGCATTC-3′; miR-124 PCR
primers, sense: 5′-ACACTCCAGCTGGGTAAGGCACG
CGGTG-3′; antisense: 5′-TGGTGTCGTGGAGTCG-3′.
U6 RT primer: 5′-AACGCTTCACGAATTTGCGT-3′; U6
PCR primers, sense: 5′-CTCGCTTCGGCAGCACA-3′;
antisense: 5′-TGGTGTCGTGGAGTCG-3′.Quantitative
RT-PCR was performed using SYBR Premix Dimer Eraser
(Vazyme Biotech co.,ltd) on a 7900HT system. GAPDH or
U6 levels were used as an internal control, and fold changes
were calculated by relative quantification (2–ΔΔCt).

Cell proliferation assay
Cells in the logarithmic phase of growth were
seeded at 3,000/well and cultured in 96-well plates.
Cell proliferation was assayed using the Cell-Counting
Kit 8 (CCK8; Dojindo Laboratories) according to the
manufacturer’s instructions at indicated time points.
Three independent experiments were performed in
triplicate.

Luciferase reporter assay

Wound healing assay

The 3’-UTR-luciferase reporter constructs
containing the 3’-UTR of AKT2 with wild-type and
mutant binding sites of miR-124 were amplified using
PCR method. The PCR products were cloned into the
pMiR-luc reporter vector (Ambion) between SpeI and
HindIII sites, immediately downstream of the luciferase
gene. The mutant 3’-UTR constructs were made by
introducing four mismatch mutations into the putative
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Cells were cultured until reached 90% confluence
in 6-well plates. Cell layers were scratched using a 10
μL tip to form wounded gaps, washed with PBS twice
and cultured. The wounded gaps were photographed
at different time points and analyzed by measuring the
distance of migrating cells from five different areas for
each wound.
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Invasion assays
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Cell invasion was determined using 24-well
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